<DOC>
	<DOC>NCT01901640</DOC>
	<brief_summary>Phase : Phase III Indication : Erectile Dysfunction Study Design : open-label, fixed dose, 6-month extension study (parent study : DA8159_EDD_III)</brief_summary>
	<brief_title>Safety Study of Once-a-Day Dosing of Udenafil to Treat Erectile Dysfunction</brief_title>
	<detailed_description>Completer from parent study(DA8159_EDD_III)continued into a 24weeks open-label extension during which they received udenafil once daily. The study concluded with a 4-week ED treatment-free period.</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Male patients aged 20 years or more diagnosed with erectile dysfunction(ED) Had uncontrolled blood pressure Had hepatic or renal dysfunction Had significant psychiatric disorders or drug abuses Was currently under anticancer chemotherapy Had a treatments for ED using other phosphodiesterase type 5(PDE5) inhibitors</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>